Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•Radiology Business
FDA Clears Multi-Disease AI Screening Platform for CT Imaging
HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
•AuntMinnie
AI Projected to Reshape Radiologist Workload But Not Eliminate Jobs
Stanford researchers predict AI could reduce radiologist hours by up to 49% over the next five years, though workforce size is likely to remain stable due to rising imaging demand.
•Cardiovascular Business
FDA Expands Clearance for AI-Guided Echo Exams on Existing Ultrasound Systems
FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.